Cargando…
NRSF and BDNF polymorphisms as biomarkers of cognitive dysfunction in adults with newly diagnosed epilepsy
Cognitive dysfunction is a common comorbidity in people with epilepsy, but its causes remain unclear. It may be related to the etiology of the disorder, the consequences of seizures, or the effects of antiepileptic drug treatment. Genetics may also play a contributory role. We investigated the influ...
Autores principales: | Warburton, Alix, Miyajima, Fabio, Shazadi, Kanvel, Crossley, Joanne, Johnson, Michael R., Marson, Anthony G., Baker, Gus A., Quinn, John P., Sills, Graeme J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academic Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4732989/ https://www.ncbi.nlm.nih.gov/pubmed/26708060 http://dx.doi.org/10.1016/j.yebeh.2015.11.013 |
Ejemplares similares
-
Molecular signatures of mood stabilisers highlight the role of the transcription factor REST/NRSF
por: Warburton, Alix, et al.
Publicado: (2015) -
Investigating imaging network markers of cognitive dysfunction and pharmacoresistance in newly diagnosed epilepsy: a protocol for an observational cohort study in the UK
por: de Bézenac, Christophe, et al.
Publicado: (2019) -
The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial
por: Marson, Anthony, et al.
Publicado: (2021) -
The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial
por: Marson, Anthony, et al.
Publicado: (2021) -
REST Is Not Resting: REST/NRSF in Health and Disease
por: Jin, Lili, et al.
Publicado: (2023)